Amag Pharmaceuticals Inc Revenue Growth Rates (AMAG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amag Pharmaceuticals inc   (NASDAQ: AMAG)
 

AMAG's Revenue Growth by Quarter and Year

Amag Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMAG Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September 93.11
2nd Quarter June 52.76
1st Quarter March 68.66
FY 214.53

AMAGs Annual Revenue
Amag Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 326.55 millions
Amag Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 474.00 millions
Amag Pharmaceuticals Inc 's Revenue in the fiscal year 2017 $ 609.95 millions
Amag Pharmaceuticals Inc 's Revenue in the fiscal year 2016 $ 532.09 millions
Amag Pharmaceuticals Inc 's Revenue in the fiscal year 2015 $ 418.28 millions




AMAG Revenue third quarter 2020 Y/Y Growth Comment
Amag Pharmaceuticals inc reported Revenue increase of 10.67% year on year in the third quarter 2020, to $ 93.11 millions, this is lower than Amag Pharmaceuticals Inc 's recent average Revenue rise of 43.91%.

Looking into third quarter 2020 results within Major Pharmaceutical Preparations industry 117 other companies have achieved higher Revenue growth. While Amag Pharmaceuticals Inc ' s Revenue growth of 10.67% ranks overall at the positon no. 1381 in the third quarter 2020.


AMAG Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 1.8 % -44.35 % 4.45 %
3rd Quarter September 10.67 % -31.18 % -20.49 % 6.93 %
2nd Quarter June -32.45 % -46.59 % -7.66 % 24.31 %
1st Quarter March -9.42 % -48.21 % 4.94 % 27.6 %
FY   - -34.84 % -17.54 % -

Financial Statements
Amag Pharmaceuticals Inc 's third quarter 2020 Revenue $ 93.11 millions AMAG's Income Statement
Amag Pharmaceuticals Inc 's third quarter 2019 Revenue $ 84.13 millions Quarterly AMAG's Income Statement


AMAG Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - 6.63 % -27.91 % 2.99 %
3rd Quarter September 76.47 % 7.71 % -16.42 % -2.94 %
2nd Quarter June -23.16 % 3.05 % -0.08 % 13.57 %
1st Quarter March -23.46 % -13.98 % -7.57 % -8 %
FY (Year on Year)   - -34.84 % -17.54 % -


Back to AMAG Growth rate Comparisons >> Back to AMAG Growth rate Comparisons >>


Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #118
Healthcare Sector #284
Overall #1381

Revenue Y/Y Growth Statistics
High Average Low
459.15 % 43.91 % -65.77 %
(Jun 30 2015)   (Dec 31 2018)
Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #118
Healthcare Sector #284
Overall #1381
Revenue Y/Y Growth Statistics
High Average Low
459.15 % 43.91 % -65.77 %
(Jun 30 2015)   (Dec 31 2018)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Amag Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
108.88 % 6.09 % -94.51 %
(Dec 31 2014)  


AMAG's III. Quarter Q/Q Revenue Comment
Amag Pharmaceuticals inc achieved in the III. Quarter 2020 above company average sequential Revenue jump of 76.47%, to $ 93.11 millions, from $52.76 millions in the second quarter.
AMAG is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Amag Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 480.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #140
Overall #480
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #140
Overall #480
Revenue Q/Q Growth Statistics
High Average Low
108.88 % 6.09 % -94.51 %
(Dec 31 2014)  


AMAG's III. Quarter Q/Q Revenue Comment
Amag Pharmaceuticals inc achieved in the III. Quarter 2020 above company average sequential Revenue jump of 76.47%, to $ 93.11 millions, from $52.76 millions in the second quarter.
AMAG is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Amag Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 480.


Amag Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)
Cumulative Revenue 12 Months Ending $ 304.23 $ 295.25 $ 320.61 $ 327.75 $ 326.17
Y / Y Revenue Growth (TTM) -6.73 % -18.95 % -25.86 % -34.84 % -43.1 %
Year on Year Revenue Growth Overall Ranking # 3732 # 2346 # 2369 # 2746 # 1176
Seqeuential Revenue Change (TTM) 3.04 % -7.91 % -2.18 % 0.49 % -10.46 %
Seq. Revenue Growth (TTM) Overall Ranking # 2757 # 700 # 1915 # 3568 # 2932


Cumulative Revenue growth Comment
Amag Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2020. If the fiscal year would end in Sep 30 2020, Amag Pharmaceuticals Inc 's annual Revenue decrease would be -6.73% year on year to $304 millions.

In the Healthcare sector 519 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2346 to 3732.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 166
Healthcare Sector # 520
Overall # 3732

Revenue TTM Y/Y Growth Statistics
High Average Low
290.76 %
 31.54 %
-43.1 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 166
Sector # 428
S&P 500 # 2757
Cumulative Revenue growth Comment
Amag Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2020. If the fiscal year would end in Sep 30 2020, Amag Pharmaceuticals Inc 's annual Revenue drop would be -6.73% year on year to $304 millions.

In the Healthcare sector 519 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2346 to 3732.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 166
Healthcare Sector # 520
Overall # 3732

Revenue TTM Y/Y Growth Statistics
High Average Low
290.76 %
31.54 %
-43.1 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 166
Sector # 428
S&P 500 # 2757




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMAG's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2020
Pro dex Inc 18.65%$ 18.646 millions
Titan Pharmaceuticals Inc 18.27%$ 18.268 millions
Silk Road Medical Inc 17.86%$ 17.861 millions
Wave Life Sciences Ltd 17.79%$ 17.788 millions
Gilead Sciences Inc 17.36%$ 17.363 millions
10x Genomics Inc 17.33%$ 17.335 millions
Axogen inc 17.03%$ 17.028 millions
Infusystem Holdings Inc16.92%$ 16.920 millions
Antares Pharma Inc 16.61%$ 16.606 millions
Cryoport inc 16.58%$ 16.582 millions
Pulmonx Corporation16.56%$ 16.564 millions
Neurocrine Biosciences Inc 16.39%$ 16.392 millions
Phenomex Inc 16.22%$ 16.219 millions
Sonoma Pharmaceuticals Inc 16.12%$ 16.123 millions
Royalty Pharma Plc15.97%$ 15.965 millions
Personalis Inc 15.52%$ 15.525 millions
Bio rad Laboratories Inc 15.45%$ 15.452 millions
Elanco Animal Health Incorporated15.34%$ 15.338 millions
Travere Therapeutics Inc 15.25%$ 15.248 millions
Luna Innovations Inc14.27%$ 14.272 millions
Addus Homecare Corp14.24%$ 14.242 millions
Apollo Endosurgery inc 13.92%$ 13.918 millions
Navidea Biopharmaceuticals Inc 13.33%$ 13.335 millions
Nature s Sunshine Products inc 13.25%$ 13.246 millions
Henry Schein Inc 13.21%$ 13.209 millions
Harrow Inc 12.89%$ 12.889 millions
Zoetis Inc 12.75%$ 12.753 millions
Incyte Corporation12.52%$ 12.521 millions
National Vision Holdings Inc 12.38%$ 12.376 millions
Insmed Inc12.24%$ 12.236 millions


About Amag Pharmaceuticals Inc Revenue Growth Rates (AMAG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.